|Bid||3.61 x 1400|
|Ask||3.85 x 2900|
|Day's Range||3.6300 - 3.7600|
|52 Week Range||2.9400 - 9.9800|
|Beta (3Y Monthly)||1.72|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 12, 2018 - Feb 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.21|
T2 Biosystems, Inc. (TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that John McDonough, president and chief executive officer, is scheduled to present at the 8th Annual SVB Leerink Global Healthcare Conference. Mr. McDonough and John Sprague, chief financial officer, will be available for one-on-one meetings during the conference. The presentation will be webcast live and available for replay, and may be accessed by visiting the Investors/Events & Presentations section of the Company’s website at www.t2biosystems.com.
LEXINGTON, Mass., Feb. 20, 2019 -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical.
T2 Biosystems, Inc. (TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, was recognized today by Fast Company among the top 10 of the world’s most innovative companies in the biotech category. The award comes just over 6 months after the launch of the T2Bacteria® Panel, the first and only FDA-cleared test to identify sepsis-causing pathogens directly from whole blood in 3 to 5 hours without the wait for blood culture, which can take 1 to 6 days or more. It is one of several panels that are approved or in development that are run on the Company’s T2Dx® Instrument, which is powered by miniaturized magnetic resonance (T2MR®) technology.
The inducement awards consist of options to purchase 30,500 shares of T2 Biosystems common stock and have a ten-year term. The exercise price of the options is $3.56, which was the per-share closing price of T2 Biosystems common stock on the Nasdaq Capital Market on February 1, 2019.
LEXINGTON, Mass., Jan. 23, 2019 -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare,.
In 2007 John McDonough was appointed CEO of T2 Biosystems, Inc. (NASDAQ:TTOO). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll Read More...
Out of thousands of stocks that are currently traded on the market, it is difficult to determine those that can really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
NEW YORK, Nov. 29, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
A look at the shareholders of T2 Biosystems Inc (NASDAQ:TTOO) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge Read More...
Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems
On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 25 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...